LivaNova PLC (LIVN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation.

Total Revenue Chart for LivaNova PLC

LivaNova PLC (LIVN) revenue for FY2025 was USD 1.4B, a 10.7% change from FY2024. LivaNova PLC's revenue grew from USD 100.0K in 1992 to USD 1.4B in 2025 (1388000.0% over 33 years). Earnings per share grew from USD 0.24 in 2002 to USD -1.61 in 2022 (-785.1%). Revenue compound annual growth rate: 5-year CAGR of 8.2%, 10-year CAGR of 16.9%, 20-year CAGR of 12.9%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$4.12B
Implied Share Price
$74.93
Enterprise Value
$4.09B
Revenue (TTM)
$1.47B
EBITDA
$260.14M
Profit Margin
12.81%
Trailing P/E
22.17
Forward P/E
16.00
Price/Book (MRQ)
3.23
Price/Sales (TTM)
2.80
EV/EBITDA
20.03
EV/Revenue
2.80
Dividend Yield
—
Book Value
$24.07
Free Cash Flow (FY2025)
$173.20M
Free Cash Flow Yield
4.21%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.